Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Liming Shao is active.

Publication


Featured researches published by Liming Shao.


Journal of Organic Chemistry | 2016

Microwave-Assisted Synthesis of Phenanthridines by Radical Insertion/Cyclization of Biphenyl Isocyanides

Yulong Xu; Yiyi Chen; Wei Li; Qiong Xie; Liming Shao

A rapid microwave-assisted approach for the synthesis of phenanthridine derivatives from the radical insertion/cyclization reaction of biphenyl isocyanides with a C(sp(3))-H bond adjacent to a heteroatom has been developed. The protocol achieves wide substrate scope and good to excellent yields. The kinetic isotope effect (KIE) studies, radical inhibition studies, and Hammett plot analysis clearly disclose that the current reaction supports a radical mechanism.


European Journal of Medicinal Chemistry | 2018

Discovery of carbazole carboxamides as novel RORγt inverse agonists

Yafei Huang; Mingcheng Yu; Nannan Sun; Ting Tang; Fazhi Yu; Xiaoxia Song; Qiong Xie; Wei Fu; Liming Shao; Yonghui Wang

A novel series of carbazole carboxamides was discovered as potent RORγt inverse agonists using a scaffold hybridization strategy. Structure-activity relationship exploration on the amide linker, carbazole ring and arylsulfone moiety of the hybrid amide 3a led to identification of potent RORγt inverse agonists. Compound 6c was found to have a good RORγt activity with an IC50 of 58.5 nM in FRET assay, and reasonable inhibitory activity in mouse Th17 cell differentiation assay (58.8% inhibition at 0.3 μM). The binding mode of carbazole carboxamides in RORγt ligand binding domain was discussed.


Acta Pharmacologica Sinica | 2017

Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands.

Jian Shen; Xicheng Yang; Mingcheng Yu; Li Xiao; Xun-jie Zhang; Huijiao Sun; Hao Chen; Guan-xin Pan; Yurong Yan; Si-chen Wang; Wei Li; Lu Zhou; Qiong Xie; Linqian Yu; Yong-hui Wang; Liming Shao

The homomeric α7 nicotinic receptor (α7 nAChR) is widely expressed in the human brain that could be activated to suppress neuroinflammation, oxidative stress and neuropathic pain. Consequently, a number of α7 nAChR agonists have entered clinical trials as anti-Alzheimers or anti-psychotic therapies. However, high-resolution crystal structure of the full-length α7 receptor is thus far unavailable. Since acetylcholine-binding protein (AChBP) from Lymnaea stagnalis is most closely related to the α-subunit of nAChRs, it has been used as a template for the N-terminal domain of α-subunit of nAChR to study the molecular recognition process of nAChR-ligand interactions, and to identify ligands with potential nAChR-like activities.Here we report the discovery and optimization of novel acetylcholine-binding protein ligands through screening, structure-activity relationships and structure-based design. We manually screened in-house CNS-biased compound library in vitro and identified compound 1, a piperidine derivative, as an initial hit with moderate binding affinity against AChBP (17.2% inhibition at 100 nmol/L). During the 1st round of optimization, with compound 2 (21.5% inhibition at 100 nmol/L) as the starting point, 13 piperidine derivatives with different aryl substitutions were synthesized and assayed in vitro. No apparent correlation was demonstrated between the binding affinities and the steric or electrostatic effects of aryl substitutions for most compounds, but compound 14 showed a higher affinity (Ki=105.6 nmol/L) than nicotine (Ki=777 nmol/L). During the 2nd round of optimization, we performed molecular modeling of the putative complex of compound 14 with AChBP, and compared it with the epibatidine-AChBP complex. The results suggested that a different piperidinyl substitution might confer a better fit for epibatidine as the reference compound. Thus, compound 15 was designed and identified as a highly affinitive acetylcholine-binding protein ligand. In this study, through two rounds of optimization, compound 15 (Ki=2.8 nmol/L) has been identified as a novel, piperidine-based acetylcholine-binding protein ligand with a high affinity.


Journal of Organic Chemistry | 2018

Regioselective Access to 3-Aryl-1-aminoisoquinolines via Nickel(I)-Catalyzed C–C and C–N Cascade Coupling Reactions from the Substituted 2-(Cyanomethyl)benzonitriles

Xicheng Yang; Haihua Yu; Yulong Xu; Liming Shao

A novel and regioselective Ni(I) catalyzed C-C and C-N cascade coupling reactions has been developed. The cascade furnishes atom-economic access to 40 3-aryl-1-aminoisoquinolines. The regioselectivity of C(sp3)-cyano group over C(sp2)-cyano group was revealed and supported by mechanism studies as well as the preliminary density functional theory (DFT) calculations.


Bioorganic & Medicinal Chemistry Letters | 2018

Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib

Yulong Xu; Xicheng Yang; Yiyi Chen; Hao Chen; Huijiao Sun; Wei Li; Qiong Xie; Linqian Yu; Liming Shao

A series of structurally novel proteasome inhibitors 1-12 have been developed based rational topology-based scaffold hopping of bortezomib. Among these novel proteasome inhibitors, compound 10 represents an important advance due to the comparable proteasome-inhibitory activity (IC50 = 9.7 nM) to bortezomib (IC50 = 8.3 nM), the remarkably higher BEI and SEI values and the effectiveness in metabolic stability. Therefore, compound 10 provides an excellent lead suitable for further optimization.


Bioorganic & Medicinal Chemistry | 2018

7 β -Methyl substituent is a structural locus associated with activity cliff for nepenthone analogues

Huijiao Sun; Yu-hua Wang; Congmin Yuan; Ling-hui Kong; Xue-Jun Xu; Yu-Jun Wang; Hai-hao Wu; Cheng Lin; Yuanyuan Qian; Huo-ming Huang; Li Xiao; Xiao Liu; Qian He; Sheng-yang Fang; Dengqi Xue; Xicheng Yang; Hao Chen; Yilin Zheng; Lan Zheng; Linqian Yu; Qiong Xie; Wei Fu; Wei Li; Jing-Gen Liu; Zhuibai Qiu; Liming Shao

With the purpose of identifying novel selective κ opioid receptor (KOR) antagonists as potential antidepressants from nepenthone analogues, starting from N-nor-N-cyclopropylmethyl-nepenthone (SLL-020ACP), a highly selective and potent KOR agonist, a series of 7β-methyl-nepenthone analogues was conceived, synthesized and assayed on opioid receptors based on the concept of hybridization. According to the pharmacological results, the functional reversal observed in orvinol analogues by introduction of 7β-methyl substituent could not be reproduced in nepenthone analogues. Alternatively, introduction of 7β-methyl substituent was associated with substantial loss of both subtype selectivity and potency but not efficacy for nepenthone analogues, which was not found in 7β-methyl orvinol analogues. Surprisingly, SLL-603, a 7β-methyl analogue of SLL-020ACP, was identified to be a KOR full agonist. The possible molecular mechanism for the heterogeneity in activity cliff was also investigated. In conclusion, 7β-methyl substituent was a structural locus associated with activity cliff and demonstrated as a pharmacological heterogeneity between nepenthone and orvinol analogues that warrants further investigations.


ACS Chemical Neuroscience | 2017

The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent κ-Opioid Agonistic Activities

Wei Li; Jian-Dong Long; Yuanyuan Qian; Yu Long; Xue-Jun Xu; Yu-Jun Wang; Qing Shen; Zuo-Neng Wang; Xicheng Yang; Li Xiao; Hongpeng Sun; Yulong Xu; Yiyi Chen; Qiong Xie; Yong-Hui Wang; Liming Shao; Jing-Gen Liu; Zhuibai Qiu; Wei Fu

To develop novel analgesics with no side effects or less side effects than traditional opioids is highly demanded to treat opioid receptor mediated pain and addiction issues. Recently, κ-opioid receptor (KOR) has been established as an attractive target, although its selective agonists could bear heterogeneous pharmacological activities. In this study, we designed and synthesized two new series of nepenthone derivatives by inserting a spacer (carbonyl) between 6α,14α-endo-ethenylthebaine and the 7α-phenyl substitution of the skeleton and by substituting the 17-N-methyl group with a cyclopropylmethyl group. We performed in vitro tests (binding and functional assays) and molecular docking operations on our newly designed compounds. The results of wet-experimental measures and modeled binding structures demonstrate that these new compounds are selective KOR agonists with nanomolar level affinities. Compound 4 from these new derivatives showed the highest affinity (Ki = 0.4 ± 0.1 nM) and the highest selectivity (μ/κ = 339, δ/κ = 2034) toward KOR. The in vivo tests revealed that compound 4 is able to induce stronger (ED50 = 2.1 mg/kg) and much longer antinociceptive effect than that of the typical KOR agonist U50488H (ED50 = 4.4 mg/kg). Therefore, compound 4 can be used as a perfect lead compound for future design of potent analgesics acting through KOR.


Expert Opinion on Therapeutic Patents | 2014

Triple reuptake inhibitors: a patent review (2006 - 2012).

Liming Shao; Wei Li; Qiong Xie; Hong Yin


Translational perioperative and pain medicine | 2016

Major Depressive Disorder and Kappa Opioid Receptor Antagonists

Wei Li; Huijiao Sun; Hao Chen; Xicheng Yang; Li Xiao; Renyu Liu; Liming Shao; Zhuibai Qiu


Organic and Biomolecular Chemistry | 2017

Microwave-assisted synthesis of hydroxyl-containing isoquinolines by metal-free radical cyclization of vinyl isocyanides with alcohols

Dengqi Xue; Hao Chen; Yulong Xu; Haihua Yu; Linqian Yu; Wei Li; Qiong Xie; Liming Shao

Collaboration


Dive into the Liming Shao's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge